Lataa...
The cost-effectiveness of biopharmaceuticals: A look at the evidence
Due to the increasing availability and costs of biopharmaceuticals, policymakers are questioning whether they provide good value relative to other health interventions and many are increasingly relying on cost-utility analyses (CUAs) to supplement decision-making. Analyzing data from the Tufts Medic...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Landes Bioscience
2012
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3361664/ https://ncbi.nlm.nih.gov/pubmed/22377753 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.4.2.18812 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|